The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | KCRD induction for NDMM: Myeloma XI trial analysis by molecular risk
Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives us an update on the analysis of the UK Myeloma XI trial (NCT01554852) by molecular risk from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. This trial investigated the efficacy of the quadruplet induction regimen of carfilzomib, cyclophosphamide, lenalidomide and dexamethasone for newly diagnosed multiple myeloma patients.
